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Abstract
Background: Although the pathophysiological mechanisms of arterial hypertension are different in obese and lean
patients, hypertension guidelines do not include specific recommendations for obesity-related hypertension and,
therefore, there is a considerable uncertainty on which antihypertensive drugs should be used in this condition.
Moreover, studies performed in general population suggested that some antihypertensive drugs may increase body
weight, glycemia and LDL-cholesterol but it is unclear how this impact on drug choice in clinical practice in the
treatment of obese hypertensive patients. Therefore, in order to identify current preferences of practitioners for
obesity-related hypertension, in the present work we evaluated antihypertensive drug therapy in a cohort of 129
pharmacologically treated obese hypertensive patients (46 males and 83 females, aged 51.95 ± 10.1 years) that
came to our observation for a nutritional consultation.
Methods: Study design was retrospective observational. Differences in the prevalence of use of the different
antihypertensive drug classes among groups were evaluated with χ2 square analysis. Threshold for statistical
significance was set at p < 0.05.
Results: 41.1 % of the study sample was treated with one, 36.4 % with two and the remaining 22.5 % with three or
more antihypertensive drugs. In patients under single drug therapy, β-blockers, ACEIs and ARBs accounted each for
about 25 % of prescriptions. The prevalence of use of β-blockers was about sixfold higher in females than males.
Diuretics were virtually never used in monotherapy regimens but were used in more than 60 % of patients on dual
antihypertensive therapy and in all patients assuming three or more drugs. There was no significant difference in
the prevalence of use of any of the aforementioned drugs among patients with obesity of type I, II and III or
between patients with or without metabolic syndrome.
Conclusions: Our data show that no first choice protocol seems to be adopted in clinical practice for the
treatment of obesity-related hypertension. Importantly, physicians do not seem to differentiate drug use according
to the severity of obesity or to the presence of metabolic syndrome or to avoid drugs known to detrimentally
affect body weight and metabolic profile in general population.
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Overweight and obesity are major risk factors for ar-
terial hypertension [1]. Large epidemiological studies
showed that the prevalence of hypertension increases
with body weight and is almost doubled in frank
obesity [1]. Specifically, about 34 % of normal weight
patients are hypertensive whereas this percentage
rises up to 60 % in overweight and exceeds 70 % in
obese patients [2]. Moreover, the majority of the
hypertensive patients seen by general practitioners are
overweight or obese [2]. Perspective studies also
showed that in non-hypertensive subjects, overweight
does increase the chance of later developing new ar-
terial hypertension [3].
Mounting evidence supports the idea that different
pathogenetic mechanisms are responsible for obesity-re-
lated hypertension and for hypertension of lean subjects
[1, 4]. Specifically, the main determinant of hyperten-
sion in lean people is peripheral vasoconstriction,
whereas obesity-related hypertension depends on sym-
pathetic nervous system hyperactivation and on the
consequent increase in cardiac output and renin and al-
dosterone release [1, 4]. The mechanism responsible for
sympathetic hyperactivation in obesity seems to be related
to the release from adipose tissue of substances such as
adipokines, inflammatory cytokines and free fatty acids
that may activate autonomic neurotransmission either dir-
ectly or indirectly, by affecting insulin sensitivity [1, 4–6].
Moreover angiotensin-II (Ang II) and aldosterone that
raise blood pressure and promote Na+ retention, are both
synthesized in adipose tissue [1, 7]. Nonalcholic fatty liver
disease (NAFDL) [8, 9] that often coexists with obesity,
also has a significant role both in activating the renin-
angiotensin-aldosterone (RAA) system and in causing
insulin resistance. NAFDL may actually represent and in-
dependent cardiovascular risk factor [10] that according
to current guidelines, can be corrected lifestyle and diet-
etic treatment [11].
There is still a considerable uncertainty on which
should be the best pharmacological approach to treat
obesity-related hypertension and major guidelines do
not expressly address this point [12–14]. Because of
the above mentioned pathophysiological differences
between lean and obesity-related hypertension, it was
suggested that drugs targeting the pathogenetic mech-
anism of obesity-related hypertension should be pre-
ferred in this condition [1, 15]. Specifically, drugs
targeting the RAA system could be a rational choice
because of Ang II and aldosterone release from the
adipose tissue [16]. β-blockers could also be an option
because they counteract the sympathetic overactiva-
tion occurring in this condition [1]. However, it has
been strongly suggested that when prescribing drug
therapy in obesity-related hypertension, the effect oftreatment on body weight and metabolic profile
should be carefully considered. Indeed, a note of cau-
tion has been raised on the use β-blocker and thiazide
diuretics because of the possible detrimental effect of
these drugs on body weight and metabolic control
[17–19]. The scenario is even more complicated when
multiple antihypertensive drugs are required as very
often happens in patients with obesity-related hyper-
tension because of the poor responsiveness of this dis-
ease to single drug therapy [1, 20]. The detrimental
effect on metabolism and body weight of selected anti-
hypertensive drugs is, indeed, greatly increased when
they are used in combinations as, for instance, in the
case of thiazide diuretics and β-blockers [21]. In the
absence of guideline directions it is unclear how, in
clinical practice, these safety concerns influence the
choice of antihypertensive therapy for obese patients
and whether, because of these concerns, different
drugs are used in people with different degrees of
obesity. Therefore, in the present paper, we performed
a retrospective study on a cohort of pharmacologically-
treated obese patients that came to our observation
for a nutritional consultation, with the aim of identi-
fying which antihypertensive drugs were more often
used in obesity-related hypertension in a real clinical
context.
Methods
Study design
This was a retrospective study. Study sample was com-
posed of 129 obese hypertensive patients (BMI ≥ 30) that
came to our observation at the Physiology Nutrition
Unit of the Federico II University of Naples for a
dietitian advice. Only patients with uncomplicated arter-
ial hypertension were included in the study whereas
those with angina, arrhythmias or heart failure were ex-
cluded. Because of the retrospective design of the study
ethical approval was waived according to current Italian
legislation (Agenzia Italiana del Farmaco, Determina-
zione 20 Marzo 2008, Gazzetta Ufficiale della Repubblica
Italiana n° 76, 31-3-2008). From the medical records of
these patients we retrieved information on age, sex, sys-
tolic and diastolic blood pressure and the complete med-
ical history including the list of all the drugs taken at the
time of evaluation. In addition, we recollected anthropo-
metric and body composition data that are routinely re-
corded during patient evaluation at our unit including
height, body weight (BW), waist circumference (WC),
total (TBW%) and extracellular (ECW%) water and fat
(FM%), fat free (FFM%) and muscle mass (MM% of
FFM). Body composition was assessed by bioelectrical
impedance analysis using a tetrapolar, 50 kHz bioelectrical
impedance analyzer (BIA 101 RJL, Akern Bioresearch,
Firenze, Italy) [22]. Visceral adiposity was estimated by
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indicator of visceral fat mass [23], using the following
equations:
FemaleVAI ¼ WC
36:58þ 1:89 BMIð Þ
 
 TG
0:81
 
 1:52
HDL
 
MaleVAI ¼ WC
39:68þ 1:88 BMIð Þ
 
 TG
1:03
 
 1:31
HDL
 
Patients were classified in two groups according to
whether their VAI values were above or below the cut-
off values that Amato et al. [24] identified as cardiovas-
cular risk discriminants in Caucasian. Because these
values differ in different age groups, we first stratified
patients according to their age, then we attributed each
of the patients of each age group either to the high or
low cardiovascular risk VAI group and, then we pooled
altogether people of different age either in the group
with VAI below or in the group with VAI above the cut-
off value.
Blood chemicals measurements including glycemia,
total HDL- and LDL-cholesterol, serum albumin and
total protein and transaminases were also obtained.
Statistical analysis
Statistical analysis was performed with the IBM Statis-
tical Package for Social Science (SPSS) Advanced Statis-
tics software (release 20.0) (Armonk, New York, USA).
Continuous data were examined for normality with the
Shapiro-Wilk test. Normally distributed data are re-
ported as mean ± standard deviation whereas the median
with the 25–75 percentiles is shown for not normally
distributed and categorical data.
Patients were classified based on the number of
anthypertensive drugs that they were treated with
(one, two and three or more) and on the pharmaco-
logical class these drugs belonged to (ACEIs, ARBs,
Ca2+-channel antagonists, β-blockers and diuretics).
Student’s t test and Mann-Whitney U test were used
for two group comparisons of normally and not-
normally distributed data, respectively. Differences in
the prevalence of the different antihypertensive drug
classes in males and females were evaluated with χ2
square analysis. Threshold for statistical significance
was set at p < 0.05.
Results
Characteristics of the study sample
Study sample consisted of 129 patients (aged 51.95 ±
10.1 years) with obesity-related hypertension all pharma-
cologically treated. 46 patients were males and the
remaining 83 were females (36 in premenopausal and 47
in postmenopausal status). Table 1 reports the mean an-
thropometric, body composition and biochemical data ofthe study population. 59 patients had class I, 34 class II
and 36 class III obesity. 41.1 % of the study sample re-
ceived a single antihypertensive drug, 36.4 % a combin-
ation of two antihypertensive drugs and the remaining
22.5 % three or more antihypertensive drugs. No signifi-
cant difference was observed in the age of the patients
one, two and three or more drugs (Table 2). 16 patients
were also treated with lipid-lowering agents, 4 with anti-
diabetic drugs and 5 with both antidiabetic and lipid-
lowering drugs.
Antihypertensive drugs used in monotherapy, dual
therapy and in multiple drug therapy
Table 2 reports the prevalence of use of different antihy-
pertensive drug classes in patients treated with one, two
and three or more antihypertensive drugs. In patients on
monotherapy, no single class was prevalent over the
others and β-blockers, ACEIs and ARBs accounted each
for about 25 % of prescriptions. Ca2+ channel blockers
(CCBs) were used in about 13 % and diuretics in about 2
% of patients. A similar pattern of drug use was observed
also when patients treated with lipid-lowering or
hypoglycemic drugs were excluded from the analysis.
When the two sexes were separately examined, a strong
gender-related difference emerged only in the preva-
lence of use of β-blockers that was about sixfold
higher in females than males.
The most remarkable difference that we noticed when
we compared patients on monotherapy with those
treated with two or more drugs was a markedly higher
use of diuretics. These drugs were virtually absent in
monotherapy regimens but were used in more than
60 % of patients on dual antihypertensive therapy and
in all patients assuming three or more drugs. Preva-
lence of use of CCBs was not significantly different in
patients on mono- or dual-therapy whereas it signifi-
cantly increased in patients treated with three or
more drugs. In this group, about 35 % of patients as-
sumed CCBs with a strong difference between sexes.
Indeed, more than 60 % of males and less than 10%
of females were treated with these drugs. ACEIs and
ARBs were used by about 40 % and 50 % of patients
under dual therapy, respectively, with a significant sex
difference in ACEI prescription that was more preva-
lent in males than in females (Table 2). Remarkably,
in patients treated with three or more drugs, ARBs
were used more often than ACEIs.
Antihypertensive drugs utilization in patients with
different degrees of obesity
To establish whether different drugs are prescribed in
patients with different degrees of obesity we stratified
our patients according to their BMI and compared the
prevalence of use of β-blockers, ACEIs, ARBs, CCBs,
Table 1 Anthropometric and metabolic data of the whole patient cohort and of patients taking only antihypertensive drugs
Whole patient cohort Patients not taking antidiabetic and/or lipid lowering
drugs
All patients
(n = 129)
Males
(n = 46)
Females
(n = 83)
All patients
(n = 104)
Males
(n = 30)
Females
(n = 74)
Age (yr) 51.95 ± 10.1 51.4 ± 9.6 52.3 ± 10.5 50.9 ± 10.1 49.4 ± 10.2 51.5 ± 10.1
Weight (kg) 95.8 ± 13.8 102.7 ± 12.3 91.9 ± 13.1** 94.4 ± 13.2 100.2 ± 11.9 92.0 ± 13.1*
Height (cm) 161.8 ± 9.4 171.6 ± 6.7 156.4 ± 5.5* 160.6 ± .8.5 1.7 ± .05 160 ± 5.7**
Systolic Arterial Pressure (mmHg) 130.0 (125–140) 130.0 (125–140) 130.0 (125–140) 130.0 (125–140) 132.0 (128.8–140.0) 130.0 (125–140)
Diaystolic Arterial Pressure
(mmHg)
85.0 (75.0–90.0) 85.0 (80.0–91.3) 85.0 (75.0–90.0) 85.0 (75.0–90.0) 85.0 (80.0–91.3) 85.0 (75.0–90.0)
WC (cm) 112.8 ± 10.5 116.1 ± 9.3 110.9 ± 10.7* 111.8 ± 9.8 114.3 ± 8.3 110.7 ± 10.3
BMI (kg/m2) 35.5 (32.4–40.7) 33.7 (32.0–37.6) 36.7 (33.5–42.0)* 35.7 (32.4–40.6) 33.1 (31.8–36.8) 36.9 (33.5–41.5)*
VAI 1.9 (1.2–2.8) 2.1 (1.4–3.1) 1.8 (1.2–2.6) 1.8 (1.2–2.6) 2.0 (1.4–3.5) 1.8 (1.2–2.5)
TBW% 44.9 ± 5.6 50.6 ± 2.9 41.7 ± 3.9** 44.3 ± 5.4 50.8 ± 2.9 41.7 ± 3.8**
ECW% 43.0 ± 4.4 41.4 ± 4.1 43.9 ± 4.4** 43.1 ± 4.5 40.8 ± 3.7 44.1 ± 4.5**
FM% 39.8 ± 7.5 32.5 ± 4.3 43.8 ± 5.6** 40.3 ± 7.6 31.6 ± 4.6 43.8 ± 5.4**
MM% 42.3 ± 8.4 45.0 ± 8.6 40.8 ± 7.9 42.2 ± 8.2 46.2 ± 8.2 40.6 ± 7.6
Plasma Glusose (mg/dl) 98.0 (91.0–107.0) 101.0 (93.5–112.0) 96.0 (88.0–107.0) 96.5 (88.8–106.0) 99.0 (92.0–107.0) 95.0 (87.0–105.5)
Total Cholesterol (mg/dl) 201.0 ± 40.3 196.8 ± 44.1 203.3 ± 38.1 204.8 ± 38.9 210.3 ± 41.7 202.6 ± 37.9
HDL Cholesterol (mg/dl) 49.0 ± 11.4 41.7 ± 9.4 53.0 ± 10.5** 49.8 ± 11.5 41.5 ± 9.4 53.1 ± 10.6**
LDL Cholesterol (mg/dl) 134.2 ± 38.1 118.1 ± 34.8 143.6 ± 37.4 127.9 ± 36.1 133.1 ± 39.7 125.8 ± 34.6
Triglycerides (mg/dl) 131.0 (92.0–169.5) 143.0 (103.3–211.8) 118.0 (85.0–158.0)* 123.0 (88.3–168.8) 148.5 (102.3–227.5) 116.5 (82.5–154.3)*
Triglycerides/HDL ratio 2.7 (1.7–3.8) 3.5 (2.3–5.3) 2.3 (1.5–3.1)** 2.5 (1.6–3.5) 3.5 (2.3–5.8) 116.5 (82.5–154.3)**
SGOT 23.0 (18.0–29.5) 26.0 (21.8–36.0) 21.0 (17.0–25.0)** 23 (18–19) 28.0 (22.0–36.0) 21.0 (17.0–25.0)**
SGPT 28.0 (19.0–43.5) 43.0 (28.0–61.3) 22.0 (16.0–31.0)** 27 (18.5–41) 43.0 (28.0–61.0) 22.0 (16.8–31.0)**
*p < 0.05 vs males
**p < 0.01 vs males
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Table 3 we did not find any significant difference in the
prevalence of use of any of the aforementioned drugs
among patients with type I, II and III obesity.
Because BMI does not reflect only the amount of fat
in the body but it is also influenced by lean tissue mass,
it could not represent the best parameter to quantify the
the impact of obesity on arterial blood pressure. Recent
evidence suggests that specific age-related cut-off values
of the visceral adiposity index, a parameter that faithfully
represent metabolically active visceral fat [23], could
identify people with high cardiovascular risk [24]. There-
fore, we compared the use of the different classes of an-
tihypertensive drugs in patients above and below this
cut-off value. The results reported in Table 4, did not
show any significant difference with the only exception
of ARB use that was higher in patients with values of
VAI above cut-off. However, this difference was signifi-
cant only if the whole patient population was considered
and not if patients receiving only antihypertensive drugs
were evaluated (Table 4).Antihypertensive drugs used in patients with or without
metabolic syndrome
67 (51.9 %) of the 129 patients of the whole population
and 49 (47.1 %) of the 104 treated only with antihyper-
tensive drugs had metabolic syndrome according to the
ATP III criteria [25]. There was no significant difference
in the prevalence of use of β-blockers, ACEIs, ARBs,
CCBs, diuretics and α1 adrenoceptor blockers in pa-
tients with or without this syndrome neither when we
considered the whole patient population or the patients
treated only with antihypertensive drugs and no antidia-
betic or lipid-lowering drugs (Table 5).
Discussion
In the present study we retrospectively evaluated the
utilization of antihypertensive drugs in a cohort of obese
hypertensive patients to establish whether in obesity-
related hypertension, practitioners preferentially use
drugs known not to negatively affect metabolism or
body weight. The main finding of our study was that, in-
stead, our obese patients were treated with drugs
Table 2 Prevalence of use of different antihypertensive drug classes in patients treated with one, two or three or more
antihypertensive drugs
Whole patient cohort Patients not taking antidiabetic and/or lipid lowering drugs
Patients treated with a single antihypertensive drug
All patients Male Female All patients Male Female
(n = 53;
50.0 ± 10.4 yr)
(n = 16;
49.6 ± 10.9 yr)
(n = 37;
50.2 ± 10.3 yr)
(n = 45;
50.0 ± 10.4 yr)
(n = 11;
48.3 ± 12.2 yr)
(n = 34;
50.2 ± 11.3 yr)
β-blockers 15 (28.3) 1 (6.3) 14 (37.8)* 12 (26.7) ------ 12 (35.3)*
ACEIs 15 (28.3) 8 (50.0) 7 (18.9)* 13 (28.9) 6 (54.5) 7 (20.6)*
ARBs 13 (24.5) 5 (31.3) 8 (21.6) 12 (26.7) 4 (36.4) 8 (23.5)
CCBs 7 (13.2) 2 (12.5) 5 (13.5) 6 (13.3) 1 (9.1) 5 (14.7)
Diuretics 1 (1.9) ------ 1 (2.7) 1 (2.2) ------ 1 (2.9)
α1 adrenergic blockers 2 (3.8) ------ 2 (5.4) 1 (2.2) ------ 1 (2.9)
Patients treated with two antihypertensive drugs
All patients Male Female All patients Male Female
(n = 47;
53.1 ± 9.5 yr)
(n = 15;
51.7 ± 8.3 yr)
(n = 32;
53.8 ± 10.1 yr)
(n = 38;
52.0 ± 8.7 yr)
(n = 10;
49.9 ± 9.1yr)
(n = 28;
52.8 ± 8.7 yr)
β-blockers 12 (25.5) 3 (20.0) 10 (31.3) 10 (26.3) 1 (10.0) 9 (32.1)
ACEIs 19 (40.4) 9 (60.0) 10 (31.3) 14 (36.8) 7 (70.0) 7 (25.0)*
ARBs 23 (48.9) 5 (33.3) 18 (56.3) 19 (50.0) 3 (30.0) 16 (57.1)
CCBs 8 (17.0) 1 (6.7) 7 (21.9) 6 (15.8) 1 (10.0) 5 (17.9)
Diuretics 30 (63.8) 11 (73.3) 19 (59.4) 26 (68.4) 8 (80.0) 18 (64.3)
α1 adrenergic blockers 1 (2.1) ------ 1 (3.1) ------- ------- -------
Patients treated with three or more antihypertensive drugs
All patients Male Female All patients Male Female
(n= 29;
53.6 ± 10.4 yr)
(n = 15;
52.9 ± 9.6 yr)
(n = 14;
54.4 ± 11.5 yr)
(n = 21;
51.3 ± 9.6 yr)
(n = 9;
50.1 ± 9.8 yr)
(n = 12;
52.3 ± 9.8 yr)
β-blockers 18 (62.1) 9 (60.0) 9 (64.3) 12 (57.1) 4 (44.4) 8 (66.7)
ACEIs 6 (20.7) 2 (13.3) 4 (28.6) 6 (28.6) 2 (22.2) 4 (33.3)
ARBs 19 (65.5) 10 (66.7) 9 (64.3) 14 (66.7) 6 (66.7) 8 (61.5)
CCBs 10 (34.5) 9 (60.0) 1 (7.1)** 8 (38.1) 7 (77.8) 1 (8.3)
Diuretics 28 (96.6) 14 (93.3) 14 (100) 21 (100) 9 (100) 12 (100)
α1 adrenergic blockers 4 (13.8) 2 (13.3) 2 (14.3) 3 (14.3) 1 (11.1) 2 (16.7)
The numbers in parentheses represent the percentage of the total of the respective group
*p < 0.05 vs males
**p < 0.01 at χ2 test
Table 3 Prevalence of use of different antihypertensive drug classes in patients with obesity of class I, II and III
β-blockers ACEIs ARBs CCBs Diuretics α1 adrenergic blockers
Whole population (n = 129) 45 (34.9) 39 (30.2) 55 (42.9) 25 (19.4) 60 (46.9) 7 (5.4)
Class I (n = 59) 13 (22.0) 25 (42.3) 23 (38.9) 16 (27.1) 26 (44.1) 1 (1.7)
Class II (n = 34) 19 (55.9) 6 (17.6) 16 (47.1) 5 (14.7) 18 (52.9) 1 (2.9)
Class III (n = 36) 13 (36.1) 8 (22.0) 16 (44.4) 4 (11.1) 16 (47.1) 5 (13.9)
Only antihypertensive (n = 104) 35 (33.7) 33 (31.7) 45 (43.3) 20 (18.3) 48 (46.2) 4 (3.7)
Class I (n = 46) 10 (21.7) 18 (39.1) 20 (43.5) 12 (26.1) 21 (45.7) 1 (2.2)
Class II (n = 29) 14 (48.3) 6 (20.7) 13 (44.8) 4 (13.8) 15 (51.7) 1 (3.4)
Class III (n = 29) 11 (37.9) 9 (31.0) 12 (41.4) 4 (13.8) 12 (41.4) 2 (6.8)
The numbers in parentheses represent the percentage of the total of the respective group
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Table 4 Prevalence of use of different antihypertensive drug classes in patients below and above the high cardiovascular risk VAI
cutoff value
β-blockers ACEIs ARBs CCBs Diuretics α1 adrenergic blockers
Whole population (n = 129) 45 (34.9) 39 (30.2) 55 (42.9) 25 (19.4) 60 (46.9) 7 (5.4)
VAI class 0 (n = 70) 25 (35.7) 25 (35.7) 24 (34.3)* 10 (14.3) 33 (47.1) 4 (5.7)
VAI class I (n = 59) 20 (33.9) 14 (23.7) 31 (52.5) 15 (25.4) 27 (45.8) 3 (5.1)
Only antihypertensive (n = 104) 35 (33.7) 33 (31.7) 45 (43.3) 20 (18.3) 48 (46.2) 4 (3.7)
VAI class 0 (n = 60) 18 (30.0) 21 (35.0) 22 (36.7) 9 (15) 29 (48.3) 2 (3.3)
VAI class I (n = 44) 17 (38.6) 12 (27.3) 23 (52.3) 11 (25) 19 (43.2) 2 (4.5)
Patients in VAI class 0 have values of VAI below the high cardiovascular risk cutoff value whereas those with values above this cutoff are in VAI class I. The
numbers in parentheses represent the percentage of the total of the respective group
*p < 0.05 vs VAI class I
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also including those expected to increase body weight or
worsen metabolic profile.
The analysis of patients on monotherapy showed that
no single antihypertensive drug was used as first choice
with the patients almost equally distributed among those
taking β-blockers, ACEIs and ARBs whereas use preva-
lence of CCBs was only slightly lower. The finding that
about 25 % of patients on monotherapy were treated
with β-blockers was unexpected. Indeed, although these
drugs may counteract the sympathetic hyperactivity that
is responsible for obesity-related hypertension, concerns
have been raised on their tolerability in this clinical
condition because current evidence suggests that they
could increase body weight and worsen metabolic status
[1, 17]. Interestingly, almost all of the patients taking β-
blockers as single drug therapy were women. A possible
explanation of this finding is that β-blockers may cause
erectile dysfunction and, therefore, are not well accepted
by male patients [26]. Thiazide diuretics were virtually
never used as single drugs in our population although
they are considered first choices drugs in current guide-
lines [12, 13]. This suggests that practitioners had the
perception that thiazide diuretics should better not be
used in obesity and that they modified their prescrip-
tions accordingly. Specifically, published evidence that
these diuretics may worsen metabolic profile and cause
impotence was probably responsible for keeping lowTable 5 Prevalence of use of different antihypertensive drug classes
β-blocker
No metabolic syndrome
Whole population (n = 62) 23 (37.1)
Only antihypertensive (n = 55) 21 (38.2)
Antihypertensive plus antidiabetic or lidip lowering drugs (n= 7) 2 (28)
Metabolic syndrome
Whole population (n = 67) 22 (32.8)
Only antihypertensive (n = 49) 14 (28.6)
Antihypertensive plus antidiabetic or lidip lowering drugs (n= 18) 8 (44.4)
The numbers in parentheses represent the percentage of the total of the respectivetheir use in our group of obese patients [18, 26, 27].
While almost never used in single drug therapy, di-
uretics were perceived as important drugs in multiple-
drug therapy as all the patients of our cohort that were
treated with three or more drugs took diuretics in vari-
ous combinations with drugs acting on RAA system and
CCBs. An interesting finding was that patients treated
with three or more drugs took less ACEIs and more
ARBs in comparison with those on monotherapy. This
was not unexpected considering that ARBs are often
used when patients stop responding to ACEIs because of
Ang II escape. Therefore we can hypothesize that pa-
tients treated with multiple drugs switched from ACEIs
to ARBs sometime before coming to our observation be-
cause of acquired drug resistance.
We did not find any significant difference in the preva-
lence of use of any drug class when comparing patients
with obesity class I, II or III. Moreover, there was no sig-
nificant difference between patients with or without
metabolic syndrome. No difference was observed also
when comparing patients with high or low values of
VAI, with the only exception of a higher prevalence of
ARB use in patients with high VAI. However, this differ-
ence was significant only when the whole patient popu-
lation also including those taking lipid lowering or
antidiabetic drugs was considered. Therefore, it probably
does not reflect different drug choice related to hyper-
tension per se but could be dependent on the presencein patients with or without metabolic syndrome
s ACEIs ARBs CCBs Diuretics α1 adrenergic blockers
18 (29.0) 27 (43.5) 11 (54.8) 32 (14.5) 2 (3.2)
15 (27.3) 26 (47.3) 9 (16.4) 29 (52.7) 1 (1.8)
3 (42.9) 1 (14.3) 2 (28.6) 3 (42.9) 1 (1.8)
21 (31.3) 28 (41.8) 14 (40.3) 28 (22.4) 5 (7.5)
17 (34.7) 19 (38.8) 11 (22.4) 20 (40.8) 3 (6.1)
4 (22.2) 9 (50.0) 3 (16.7) 8 (44.4) 2 (11.1)
group
Cataldi et al. BMC Pharmacology and Toxicology  (2016) 17:9 Page 7 of 8of a concomitant disease such as diabetes. Indeed, ARBs
(and ACEIs) could represent first choice drugs in dia-
betes especially in the presence of renal damage [12].
Collectively, our results seem to suggest that although
concerns have been raised on the use of some antihyper-
tensive drugs because of their effect on body weight and
metabolism [28–31], the degree of obesity or the pres-
ence of its metabolic complications did not influence
drug choice in our patients. These data could also sug-
gest that, in our patients, the class of antihypertensive
drugs used was not a major determinant either of BMI
or of metabolic control. However, our study was not spe-
cifically designed to address this question, and further
randomized prospective studies will be needed to ad-
dress this point also considering that available informa-
tion in the literature is very limited. Specifically, a few
studies showed that drugs acting on RAA system and, in
particular, ARBs could improve metabolic status in pa-
tients with metabolic syndrome [32], decreasing visceral
fat accumulation [33] and improving insulin sensitivity
and lipid profile [34], whereas visceral adiposity in-
creases the risk of developing adverse metabolic effects
upon treatment with β-blockers or thiazide diuretics
[35]. Moreover, an important limitation of these studies
was the short duration of drug exposure ranging around
several weeks. The issue of establishing whether adipos-
ity or metabolic status are affected by specific antihyper-
tensive drug classes in obesity is potentially clinically
relevant because, by interfering with these parameters,
drug therapy could positively or negatively influence
long term prognosis in this condition. Under this re-
spect, it is worth mentioning the recent evidence re-
ported by the Blood Pressure Lowering Treatment
Trialists’ Collaboration [36] showing that in obesity-
related hypertension the outcome measured as a com-
posite of major cardiovascular events including stroke,
coronary heart disease, heart failure, and cardiovascular
death, is independent from the class of antihypertensive
drugs taken by the patients.
Although our retrospective study was performed on
medical records from a single institution, we believe that
it is actually representative of a larger population of
obese patients. Indeed, our unit is not a primary center
for the treatment of hypertension but a nutritional con-
sultation with its catchment area extending across the
larger Naples metropolitan region. Therefore, the data
on antihypertensive drug treatment that we analyzed in
the present study do not reflect the therapeutic choices
of physicians working in a single center but those of pri-
mary care physicians or of cardiologists taking care of
the patients in many other institutions that sent us their
patients only for a nutritional advice. A limitation of the
study is that, we cannot exclude a selection bias because
the patients that we examined were actually sent to ourobservation by other physicians to further improve their
medical treatment. This implies that our study sample
could have been theoretically composed by patients tak-
ing benefits of higher standard than average medical
care.
Conclusions
In conclusion, we showed that the pharmacological ap-
proach to the treatment of obesity-related hypertension
is highly heterogeneous as different drug classes are used
either alone or in combination and no first choice proto-
col seems to be adopted in clinical practice. Importantly,
we found no evidence that physicians differentiate drug
use according to the severity of obesity, to visceral fat
accumulation or to the presence of metabolic syndrome.
There is an urgent need of further data to provide in-
formed directions that could help practitioners in choos-
ing the right therapy for hypertensive obese patients.
Specifically, well designed randomized trials are needed
to establish whether the detrimental effect of some anti-
hypertensive drugs that were observed in general popu-
lation also occur in obese patients.
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